CLVS up +1.33% percent Today $CLVS High is at 59.77 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 1:20 PM

CLVS up +1.33% percent Today $CLVS High is at 59.77 and the Low 58.36 with current volume of 103,068.

Recent News posted below.

Clovis Oncology Inc CLVS other info.
http://investorshangout.com/Clovis-Oncology-Inc-CLVS-53711/

CLVS Clovis Oncology Inc Recent Headline News

Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study
Business Wire - Wed Nov 12, 4:28PM CST
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the Phase 2 portion of the seamless Phase 2/3 TIGER-1 (Third-Generation Inhibitor of Mutant EGFR in Lung Cancer) study has commenced with the dosing of the first patient at a U.S. study site. Rociletinib is the Company's novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the primary resistance mutation T790M.
CLVS: 57.12 (-1.32)

Clovis Oncology's (CLVS) CEO Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:10PM CST

CLVS: 57.12 (-1.32)

Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:40PM CST

CLVS: 57.12 (-1.32)

Clovis misses 3Q profit forecasts
Automated Insights - Thu Nov 06, 6:39PM CST
BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Thursday reported a loss of $39.6 million in its third quarter.
CLVS: 57.12 (-1.32)

Clovis Oncology misses by $0.10
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:00PM CST

CLVS: 57.12 (-1.32)

Clovis Oncology Announces Third Quarter 2014 Operating Results
Business Wire - Thu Nov 06, 3:01PM CST
--$278.3 million raised in September sale of senior convertible notes
CLVS: 57.12 (-1.32)

Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST

BEBE: 2.42 (-0.05), ACET: 21.37 (-0.19), ANET: 77.29 (+0.05), FNGN: 32.20 (-0.08), CPST: 0.94 (-0.04), AUQ: 3.64 (+0.06), AMRN: 0.94 (+0.05), ED: 62.23 (-0.02), ENV: 54.39 (+0.14), FXCM: 16.60 (+0.04), BCEI: 38.48 (-1.67), GXP: 26.60 (-0.12), EAC: 12.56 (+0.26), DXCM: 54.18 (+0.17), CSC: 60.87 (-0.38), AEL: 27.08 (+0.23), HNSN: 0.79 (+0.03), CFN: 57.59 (+0.03), ANAC: 32.08 (+0.31), DAR: 18.74 (-0.09), GST: 3.96 (-0.12), ARC: 9.94 (+0.01), FIVN: 4.95 (+0.04), ELON: 1.93 (+0.01), FSLR: 47.87 (-1.72), EZPW: 11.21 (-0.07), ALIM: 5.24 (+0.03), FWM: 2.30 (-0.01), BRS: 71.19 (-1.58), ECOM: 18.51 (-0.25), FTEK: 3.80 (-0.18), CVT: 28.20 (-0.03), AL: 36.90 (-0.38), BBRG: 13.28 (-0.12), BPZ: 0.93 (-0.01), ECPG: 45.26 (-0.47), HTGC: 15.31 (-0.66), AIRM: 44.07 (+0.06), BNFT: 26.66 (-0.94), ENOC: 15.02 (-0.13), HPTX: 21.64 (-0.06), AGO: 24.69 (-0.03), FICO: 72.08 (+0.33), FF: 12.38 (-0.12), FI: 19.83 (-0.41), EVC: 5.25 (+0.01), EBS: 24.50 (-0.42), ABCO: 46.37 (-1.77), DIOD: 26.33 (-0.06), DIS: 90.45 (+0.55), EGOV: 17.47 (-0.12), APEI: 36.49 (-0.07), DVA: 76.98 (+0.26), CLVS: 57.09 (-1.35), HCI: 42.25 (+0.28), BRKR: 18.30 (-0.12), HGR: 21.11 (+0.40)

Clovis Oncology to Present at the 2014 Credit Suisse Healthcare Conference
Business Wire - Tue Nov 04, 3:07PM CST
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, the Company's President and CEO, will present at the 2014 Credit Suisse Healthcare Conference on Tuesday, November 11, at 2:00pm MST. The conference is being held at the Arizona Biltmore in Phoenix, Arizona.
CLVS: 57.09 (-1.35)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 104.96 (-1.94), CLVS: 57.09 (-1.35), ARWR: 6.33 (-0.20), ACHN: 14.11 (-0.74), MRK: 59.47 (+0.16), RTRX: 11.74 (+0.18), RGLS: 18.13 (-1.49), EPZM: 22.63 (-1.25), AGIO: 87.51 (+0.64), RMTI: 11.16 (-0.08), ARNA: 4.77 (+0.07), KERX: 15.64 (+0.05)

AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 4:41PM CDT
The CHMP gave a positive opinion in favour of approving AstraZeneca's (AZN) Lynparza.
AGN: 196.59 (+0.08), CLVS: 57.09 (-1.35), AZN: 74.61 (+0.35), REGN: 399.13 (-1.98)

Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer
Business Wire - Thu Oct 23, 3:52PM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer (NSCLC) has commenced and the first patient has been dosed at a U.S. study site. Lucitanib is the Company's oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a-ss).
CLVS: 57.09 (-1.35)

3 Beaten Down Biotech Stocks to Buy Now
George Budwell, The Motley Fool - Motley Fool - Thu Oct 23, 10:20AM CDT
Biotech stocks that crumble after a clinical or regulatory setback can turn out to be stellar long-term buys. Even so, it's critical to understand why the stock plunged in the first place, and how management plans on putting the company on track to...
DVAX: 15.91 (-0.13), CLVS: 57.09 (-1.35), CLDX: 14.60 (-0.21), AZN: 74.61 (+0.35), GSK: 45.78 (+0.16)

Clovis reports November 6
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:42AM CDT

CLVS: 57.09 (-1.35)

Clovis Oncology to Announce Third Quarter 2014 Financial Results and Host Webcast Conference Call on November 6
Business Wire - Wed Oct 22, 8:01AM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2014 financial results on Thursday, November 6, 2014, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company's results in greater detail.
CLVS: 57.09 (-1.35)

Fallopian Tube Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b25z3h/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Johnson & Johnson - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - MedImmune, LLC - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - ImmunoGen, Inc. - Astex Pharmaceuticals, Inc. - CTI BioPharma Corp. - Bayer AG - Incyte Corporation - Active Biotech AB - Oncolytics Biotech Inc. - OXiGENE, Inc. - Curis - Topotarget - NeoStem - Pharmacyclics - Synta - Oasmia - MabVax - Acceleron - Cerulean - OncoMed - TetraLogic Pharmaceuticals - Merrimack Pharmaceuticals, Inc. - Immunovaccine, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Lee's Pharmaceutical Holdings Limited - Clovis Oncology, Inc. - Recepta Biopharma S.A. - EGEN, Inc. - Sanofi Pasteur SA - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/b2...opian_tube
ONCY: 0.79 (-0.05), INCY: 71.83 (-0.04), IMGN: 10.13 (+0.01), AMGN: 160.91 (-1.02), LLY: 67.71 (+0.31), CTIC: 2.19 (+0.01), GSK: 45.78 (+0.16), OXGN: 1.75 (unch), MACK: 8.44 (-0.11), JNJ: 108.82 (+0.07), CLVS: 57.09 (-1.35), ABBV: 63.77 (+0.01), NVS: 94.39 (+1.73)

Nasdaq stocks posting largest percentage increases
AP - Tue Sep 30, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
LOXO: 11.26 (-0.08), TRVN: 5.72 (+0.04), UNXL: 5.38 (+0.02), GLBZ: 12.40 (-0.35), EFOI: 6.10 (-0.30), CLVS: 57.09 (-1.35), TIBX: 23.74 (+0.05), AKAO: 10.00 (-0.06), MOVE: 20.95 (-0.03)

Ford and eBay are big market movers
AP - Tue Sep 30, 3:24PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
ATHL: 58.40 (-0.01), F: 15.01 (+0.43), TK: 53.39 (-0.85), BGC: 13.88 (-0.05), MOVE: 20.95 (-0.03), MAS: 23.18 (-0.01), NWSA: 15.11 (-0.16), CTAS: 71.03 (-0.28), EBAY: 54.40 (+0.34), TIBX: 23.74 (+0.05), CLVS: 57.09 (-1.35), CVEO: 10.66 (-0.40), VIMC: 8.93 (-0.25), AMAG: 34.68 (-0.25), NWS: 14.89 (-0.11), TA: 9.05 (-0.02)

Critical Alerts For Yahoo!, Clovis Oncology, Sears Holdings, PetSmart and Endo Health Solutions Released By InvestorsObserver
PR Newswire - Tue Sep 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for YHOO, CLVS, SHLD, PETM and ENDP.
ENDP: 67.84 (-0.05), YHOO: 50.70 (+0.10), CLVS: 57.09 (-1.35), SHLD: 38.10 (+0.34), PETM: 73.12 (+0.35)

Big News for These 5 Stocks From ESMO
Brian Orelli, The Motley Fool - Motley Fool - Tue Sep 30, 8:05AM CDT
The news from the European Society for Medical Oncology meeting, or ESMO, came mostly from the large pharmas -- Roche , Merck , and AstraZeneca in particular -- but a couple of smaller biotechs are benefiting. Shares of Clovis Oncology and ...
CLVS: 57.09 (-1.35), MRK: 59.48 (+0.17), AZN: 74.61 (+0.35), BMY: 57.80 (-0.81), EXEL: 1.81 (unch)

Clovis Oncology Inc. (CLVSQ) Stock Research Links

CLVSQ Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cost of Living Tops Financial Worries in 2026

Financial Stress — The Silent Productivity Killer Down in the trenches of nine-to-five, it’s money that keeps stealing workers' peace of mind. The TELUS Mental Health Index shines a glaring spotlight on this, revealing that 58% of U.S. workers are most stressed by living costs. Now, that's a kicker when stacking it next to retirement or emergency savings. Those take...

Aardvark Therapeutics Faces Investor Legal Challenges

Behind the Screens: Aardvark's Legal Turmoil Oh boy, it's not a pretty sight when a biotech darling like Aardvark Therapeutics (NASDAQ: AARD) hits the skids. We're talking about a major shake-up folks. It seems like just yesterday this company was on the cusp of cracking into new medical terrains, promising hope where there was just uncertainty. But here we are, the...

M Social's NYC Edition Merges Sport and Community

A Bold Move in the Heart of Manhattan You know when a hotel chains itself to a major event like the US Open, it's looking to make a statement—bold, loud, and clear. M Social Hotel New York Times Square did just that, turning its space into a powerhouse hub of sport, culture, and community right in Times Square. Over two days, they brought together some of the top ATP...

Old Orchard's Fall Festival: Music, Vendors, Fun

Big Bend Turns Festive Again When it comes to fall, Old Orchard ain't shy. The quaint corner of Webster Groves is gearing up to transform Big Bend Boulevard into the sort of autumnal bash that would make even Mother Nature kick up her heels. This October 24 and 25, folks will be spilling into the streets as the Merchant & Business Association of Old Orchard (MBAOO)...

Nozomi Networks: Leading OT Security in 2026

One Year of Massive Wins for Nozomi Networks Here's a wild trajectory: Nozomi Networks has been firing on all cylinders in 2026, capturing attention not just from analysts but also from anyone with a stake in the security game. The company’s impressive run was highlighted most recently when they were crowned a Leader in The Forrester Wave: Operational Technology...

Wheaton Precious Metals Sets 2026 Investor Day Webcast

Ready for a Glimpse into Wheaton's Strategy? Gather 'round, folks, because on September 16, 2026, Wheaton Precious Metals is rolling out the carpet for its Investor Day webcast. It's more than a routine session; it's an open window into what's simmering behind Wheaton's illustrious streams of gold and silver. I mean, what's better than having a front-row seat to the...

How Shelton's Property Taxes Influence Housing Costs

Thinking about snapping up a home in Shelton, Connecticut? Well, you might want to keep an eye on those property taxes first. Sure, mortgage rates and listing prices grab all the initial attention, but taxes—oh boy, they know how to creep up on ya. Matt Nuzie from RE/MAX lays it bare: property taxes can make or break the bank for homebuyers in Fairfield County. So,...

Tradr's Bold Venture: Anthropic ETFs Ahead of IPO

Why Tradr Is Diving Into Anthropic's Hype There's a whiff of anticipation in the air as Anthropic gears up for its much-anticipated IPO, and Tradr isn't sitting on its hands here. They've just filed for two ETFs—one long, one short—ahead of the big day. We're talking about ANTT and ANTZ, betting on leveraged and inverse plays on whatever whirlwind Anthropic's stock...

Panel Eyes AI, Guidelines for Workers' Comp Claims

Tackling Workers' Comp Consistency The world of workers' comp is all set for a shake-up come National Comp 2026. With industry stalwarts gathering in Seattle, one hot topic on the table is how to turn evidence-based guidelines into everyday practice for claims. And, trust me, it's not as straightforward as slapping guidelines into a handbook. Evidence and Integration: A...

Skanska's $57M Deal to Transform Del Mar Traffic

A Roadway Overhaul in Del Mar A cool $57 million. That’s the ticket Skanska bought to scoop up the El Camino Real project in Del Mar, California. Think of it as a road facelift, a necessary one—it includes bulking up the corridor to four lanes and swapping in a spanking new San Dieguito River Bridge, taking the place of an old rascal that's been around for 84 years....